What Does AstraZeneca (AZN) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
AstraZeneca (AZN) is a global pharmaceutical company spanning oncology, cardiovascular, and rare diseases, standing out as a mega-cap name with a deep drug pipeline and steady shareholder returns. Its share price, earnings, revenue, and related stocks move in tandem with new-drug approvals and currency swings.
🏢 What kind of company is AstraZeneca?
AstraZeneca (AZN) is a multinational pharmaceutical company formed in 1999 through the merger of Sweden's Astra and the UK's Zeneca. Headquartered in the United Kingdom, it trades on the US stock market as an American Depositary Share, with oncology, cardiovascular, respiratory, and rare diseases as its core therapeutic areas.
It holds a diversified drug portfolio spanning multiple therapeutic areas: oncology (Tagrisso, Imfinzi, Calquence), cardiovascular, renal, and metabolism (Farxiga), respiratory and immunology (Symbicort), and rare diseases (built around the Alexion acquisition). It occupies a core position among the world's largest pharmaceutical groups.
💰 How does AstraZeneca make money?
| Business segment | Revenue share | Description |
|---|---|---|
| Oncology | Core | Portfolio of oncology drugs such as Tagrisso, Imfinzi, and Calquence |
| Cardiovascular, renal, and metabolism | Key growth pillar | Therapeutics for chronic conditions including Farxiga |
| Rare diseases (Alexion) | Expanding | Rare-disease lineup built around the Alexion acquisition |
| Respiratory and immunology | Legacy franchise | Inhaled and asthma therapeutics such as Symbicort |
Oncology accounts for the core share of AstraZeneca's revenue, while cardiovascular and metabolism along with rare diseases are diversifying into growth pillars. The addition of the Alexion-acquired rare-disease franchise has strengthened both the margin structure and the pipeline, while the global revenue mix also introduces translation-driven volatility tied to currency moves. Quarterly revenue momentum shifts with R&D investment and clinical outcomes — an earnings structure centered on new drugs.
📐 AstraZeneca's market cap and corporate scale
Market capitalization stands at $265.7B, with 96,100명 employees.
A mega-cap pharmaceutical name sitting at the top tier of global market caps, AstraZeneca belongs to the group commonly benchmarked against LLY, MRK, PFE, and NVS among large-cap pharma peers. Backed by stable operating cash flow, it pursues R&D investment and shareholder returns in parallel, anchoring its place as a core holding in global healthcare portfolios.
📈 AstraZeneca outlook and share-price drivers
Global expansion of the oncology pipeline and growth of the Alexion-based rare-disease franchise are the core medium- to long-term engines. Clinical progress in advanced modalities such as targeted therapy, immuno-oncology, and antibody-drug conjugates is likely to drive new-drug revenue momentum, while the diversified therapeutic portfolio cushions the blow of any single drug's patent cliff. Near-term variables include key patent expiry schedules, US and EU drug-pricing negotiations, currency moves, and clinical-result volatility.
- Global expansion of the oncology pipeline
- Growth of the Alexion-based rare-disease franchise
- Scale-up in advanced modalities such as antibody-drug conjugates and immuno-oncology
⚔️ AstraZeneca's core strengths and risks
A diversified therapeutic-area pipeline and a leading oncology position are its strengths, while patent expirations and drug-pricing regulation are its core risks.
💪 Core strengths
⚠️ Core risks
🔄 AstraZeneca competitors and related (beneficiary) stocks
Direct competitors within the global large-cap pharma bucket include MRK in oncology and immunotherapy, LLY in metabolism and oncology, PFE in broad-based diversification, and NVS as a global multinational. Among related names, the metabolic-disease rival NVO and the global vaccines and consumer-health peer JNJ are commonly grouped as adjacent names. MRK, LLY, PFE, and NVS compete head-to-head in overlapping therapeutic areas, while NVO and JNJ are evaluated as a related group that tends to move with broader healthcare-sector flows.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co Inc | $129.79 | -0.4% | $320.6B | 36.5 | 7.0 | 18.97% | 2.52% |
| LLY | Lilly(Eli) & Co | $1154.97 | -4.5% | $1.09T | 41.6 | 34.9 | 107.64% | 0.6% |
| PFE | Pfizer Inc | $24.91 | -0.9% | $142.0B | 19.1 | 1.6 | 8.29% | 6.91% |
| NVS | Novartis AG ADR | $158.44 | -0.3% | $290.0B | 23.9 | 7.0 | 30.56% | 2.8% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk ADR | $51.61 | +0.1% | $173.3B | 12.1 | 7.3 | 73.79% | 3.46% |
| JNJ | Johnson & Johnson | $255.82 | -3.7% | $616.5B | 29.6 | 7.3 | 25.74% | 2.1% |
✅ AstraZeneca investor checklist
Key points to monitor when investing in AstraZeneca. Oncology new-drug momentum, the growth pace of the Alexion rare-disease franchise, and the patent-expiry and pricing-regulation environment are the core short- and medium-term variables.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 🧬 Oncology pipeline | Prescription expansion of key oncology drugs and clinical-progress status | Expanding |
| 🩺 Rare-disease franchise | Revenue expansion trajectory of the Alexion-based lineup | Growth phase |
| 📜 Patent expiration | Patent-cliff schedule of key drugs | Requires monitoring |
| 💰 Capital return | Balance between dividends and R&D investment | Maintained steadily |
Patent expirations and drug-pricing regulation are the core near-term risks. US Inflation Reduction Act pricing negotiations and downward pressure on European drug prices are accumulating, while major Phase 3 outcomes and global revenue currency exposure can also act as potential sources of volatility.
AstraZeneca is a global pharmaceutical mega-cap operating a diversified pipeline powered by oncology leadership and rare-disease expansion. Given that patents, pricing, and clinical volatility are the core variables, dollar-cost averaging and a long-term horizon are recommended.
이 글은 2026년 5월 21일 기준 정보입니다.